Lilly Unveils New Breakthrough Data in HR+ Breast Cancer at SABCS

Eli Lilly and Company is preparing to unveil a slate of new findings at the San Antonio Breast Cancer Symposium (SABCS), running December 9–12.

The update shines a spotlight on fresh progress in HR+ breast cancer, the most common form of the disease, and reflects the company’s push to strengthen treatment across key biologic targets.

Leading the lineup is Inluriyo (imlunestrant), Lilly’s oral estrogen receptor antagonist. A late-breaking oral session will share Phase 3 EMBER-3 trial results, including an interim overall survival readout, progression-free survival updates, and time-to-chemotherapy data.

The presentation will also explore how early shifts in circulating tumor DNA may help predict patient outcomes. As the first mention of the main keyword, HR+ breast cancer research remains the driving focus of this study.

Also Read: India's Innovative Therapies Set Global Standard at Low Cost

“At SABCS 2025, we’re proud to showcase new data addressing the three key biologic targets in HR+ breast cancer—CDK4/6, estrogen receptor, and PI3K,” said Jacob Van Naarden, EVP and President of Lilly Oncology. “These presentations highlight the continued momentum of Lilly’s breast oncology portfolio and our commitment to meaningful progress for people living with breast cancer.” 

Lilly will also highlight new insights for Verzenio (abemaciclib). A poster presentation from the monarchE trial shows that Verzenio combined with endocrine therapy continues to improve overall survival, along with long-term gains in invasive disease-free survival and distant relapse-free survival in patients with high-risk early breast cancer.

Early-stage innovation rounds out the company’s presence with data on LY4064809, tested alone and alongside endocrine therapy and CDK4/6 inhibitors for PIK3CA-mutant advanced disease. The PIKALO-1 Phase 1/2 study offers updated safety, efficacy, and biomarker results, including findings across diabetic subgroups. Lilly plans to advance the therapy into the Phase 3 PIKALO-2 trial.